GSK Takes Back Control of Korean OTCs To Combine With Pfizer Megabrands
Executive Summary
GSK is set to regain the rights to a portfolio of OTC brands in South Korea which it will combine with Pfizer megabrands such as Advil and Centrum to create a sizable consumer health footprint in the country.